Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (AKBA) and Cerevel Therapeutics Holdings (CERE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Akebia Therapeutics (AKBAResearch Report) and Cerevel Therapeutics Holdings (CEREResearch Report).

Akebia Therapeutics (AKBA)

Needham analyst Serge Belanger maintained a Hold rating on Akebia Therapeutics today. The company’s shares closed last Tuesday at $0.41, close to its 52-week low of $0.35.

According to TipRanks.com, Belanger has 0 stars on 0-5 stars ranking scale with an average return of -3.6% and a 35.6% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

Akebia Therapeutics has an analyst consensus of Hold, with a price target consensus of $2.00, a 426.2% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Hold rating on the stock with a $2.00 price target.

See today’s best-performing stocks on TipRanks >>

Cerevel Therapeutics Holdings (CERE)

Berenberg Bank analyst Esther Hong reiterated a Buy rating on Cerevel Therapeutics Holdings today and set a price target of $44.00. The company’s shares closed last Tuesday at $23.03.

According to TipRanks.com, Hong ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -31.8% and a 13.5% success rate. Hong covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Aldeyra Therapeutics, and Axsome Therapeutics.

Currently, the analyst consensus on Cerevel Therapeutics Holdings is a Strong Buy with an average price target of $42.75.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AKBA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed